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Aberrant ion channel function has been heralded as a main underlying mechanism driving
epilepsy and its symptoms. However, it has become increasingly clear that treatment
strategies targeting voltage-gated sodium or calcium channels merely mask the symptoms
of epilepsy without providing disease-modifying benefits. Ion channel function is likely only
one important cog in a highly complex machine. Gross morphological changes, such as
reactive sprouting and outgrowth, may also play a role in epileptogenesis. Mechanisms
responsible for these changes are not well-understood. Here we investigate the potential
involvement of the neurite outgrowth-promoting molecule collapsin response mediator
protein 2 (CRMP2). CRMP2 activity, in this respect, is regulated by phosphorylation state,
where phosphorylation by a variety of kinases, including glycogen synthase kinase 3
β (GSK3β) renders it inactive. Phosphorylation (inactivation) of CRMP2 was decreased
at two distinct phases following traumatic brain injury (TBI). While reduced CRMP2
phosphorylation during the early phase was attributed to the inactivation of GSK3β,
the sustained decrease in CRMP2 phosphorylation in the late phase appeared to be
independent of GSK3β activity. Instead, the reduction in GSK3β-phosphorylated CRMP2
was attributed to a loss of priming by cyclin-dependent kinase 5 (CDK5), which allows for
subsequent phosphorylation by GSK3β. Based on the observation that the proportion of
active CRMP2 is increased for up to 4 weeks following TBI, it was hypothesized that it may
drive neurite outgrowth, and therefore, circuit reorganization during this time. Therefore,
a novel small-molecule tool was used to target CRMP2 in an attempt to determine its
importance in mossy fiber sprouting following TBI. In this report, we demonstrate novel
differential regulation of CRMP2 phosphorylation by GSK3β and CDK5 following TBI.
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INTRODUCTION
Precise regulation of voltage- and ligand-gated ion channels is
essential for proper function of both the peripheral and cen-
tral nervous systems. As perturbations to these tightly-controlled
systems can result in diverse neuropathologies, regulators of ion
channel function have become prime targets for therapeutic inter-
vention. We have previously demonstrated that the intracellular
phosphoprotein collapsin response mediator protein 2 (CRMP2)
is a positive regulator of both ligand- and voltage-gated cal-
cium channels (Brittain et al., 2009, 2012a) and can be targeted
as such to provide therapeutic relief (Brittain et al., 2011a,b;
Wilson et al., 2012a).While phosphorylation of CRMP2 increases
its interaction with the N-type voltage-gated calcium channel
(Brittain et al., 2012b), we recently discovered a novel posttrans-
lational modification (SUMOylation) that negatively impacts
CRMP2’s ability to enhance calcium influx (Ju et al., 2013).
Intriguingly, through SUMOylation, a previously unidentified
link between CRMP2 and trafficking of voltage-gated sodium
channels was unearthed (Dustrude et al., 2013). CRMP2 is there-
fore in the unique position of potentially possessing the ability
to impact voltage-gated calcium and sodium channels, as well
as the ligand-gated N-methyl-D-aspartate (NMDA) receptor. A
common pathology to which all three of these channel types are
thought to contribute is epilepsy (for review see Ghasemi and
Schachter, 2011; Oliva et al., 2012; Siwek et al., 2012).
Nearly 2.3 million people in the United States alone are bur-
dened by epilepsy (CDC, 2012), a neurological condition classi-
fied by spontaneously recurring seizures (Goddard et al., 1969),
with an estimated 150,000 more diagnosed each year (Hirtz
et al., 2007; England et al., 2012). It is estimated that nearly
half of epilepsy cases are classified as complex partial seizures,
the majority of which originate from foci within the temporal
lobe (Hauser and Kurland, 1975; Manford et al., 1992a,b; Larner,
1995; Panayiotopoulos, 2005). In many patients, temporal lobe
epilepsy (TLE) is initiated by a traumatic event such as trau-
matic brain injury (TBI), febrile seizures, status epilepticus (SE),
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tumors, stroke, or infection (Kharatishvili and Pitkanen, 2010;
Yang et al., 2010a; O’Dell et al., 2012). These events are often
followed by an asymptomatic latency period lasting upwards
of 10 years prior to the development of spontaneous recurring
seizures (de Lanerolle et al., 2003; Sharma et al., 2007; Yang
et al., 2010a). That these arguably diverse insults can lead to
a similar phenotype suggests the possibility of shared epilepto-
genic mechanisms. The majority of antiepileptic drugs (AEDs)
available today target the voltage-gated sodium channel. One
of these, Lacosamide (Vimpat®) (R-N-benzyl 2-acetamido-3-
methoxypropionamide) ((R)-LCM), does so through a unique
mechanism. Instead of affecting current density or steady-state
gating kinetics, (R)-LCM selectively enhances sodium channel
slow inactivation (Errington et al., 2008). Another characteristic
that sets (R)-LCM apart from other AEDs is its ability to tar-
get CRMP2 (Beyreuther et al., 2007; Park et al., 2009). Notably,
expression levels of CRMP2 have been shown to alter the abil-
ity of (R)-LCM to impact sodium channel function (Wang et al.,
2010).
Given CRMP2’s remarkable ability to regulate ion channel
function, it can be at times difficult to consider its many other
functions, particularly those for which it was first identified
(i.e., neurite outgrowth and guidance) (Goshima et al., 1995).
Importantly, of the myriad of CRMP2 functions, it is the ability
to promote neurite outgrowth that is impacted by (R)-LCM,
not those associated with ion channel function (Wang and
Khanna, 2011; Wilson et al., 2012b). CRMP2 promotes neurite
outgrowth by two distinct mechanisms: (Brittain et al., 2009)
binding and transporting tubulin dimers from the soma to
distal projections (Fukata et al., 2002; Kimura et al., 2005) and
(Brittain et al., 2012a) stabilizing the growing end of the micro-
tubule by promoting the inherent GTPase activity of tubulin
(Chae et al., 2009), the latter of which is impaired by (R)-LCM
(Wilson et al., 2012b). Aberrant growth and reorganization of
neuronal circuits, specifically that of the dentate mossy fibers
within the hippocampus, is commonly observed in post-mortem
tissue samples from TLE patients and in animal models of
the disease (for review see Koyama and Ikegaya, 2004; Sutula,
2004). Notably, CRMP2 was recently suggested to be involved
in mossy fiber sprouting in the SE model of TLE (Lee et al.,
2012). Under normal conditions, mossy fibers project from the
granule cell layer of the dentate gyrus into the CA3 region of
the hippocampus where they form synapses with pyramidal cells
(Andersen et al., 1969). During TLE, mossy fibers are observed to
innervate the inner molecular layer where they synapse onto the
dendrites of other dentate granule cells, leading to the formation
of recurrent excitatory circuits (Blaabjerg and Zimmer, 2007).
To date, the molecular mechanisms contributing to mossy fiber
sprouting are relatively unknown. Recent focus has centered on
the involvement of growth-factor cascades, particularly that of
the tropomycin-related kinase receptor B (TrkB). Activation of
the TrkB receptor eventually leads to the phosphorylation and
inactivation of glycogen-synthase kinase β (GSK3β) by protein
kinase B (Akt) (Cross et al., 1995; Alessi et al., 1996; Bhave et al.,
1999). Inactivation of GSK3β has been observed following insults
commonly associated with TLE, such as TBI (Shapira et al., 2007;
Dash et al., 2011; Zhao et al., 2012), hypoxia-ischemia (Sasaki
et al., 2001; Endo et al., 2006; Xiong et al., 2012), and SE (Lee
et al., 2012).
The ability of CRMP2 to promote neurite outgrowth is gov-
erned by its phosphorylation state. Phosphorylation by a variety
of kinases, including GSK3β, renders CRMP2 inactive (Arimura
et al., 2000, 2005; Brown et al., 2004; Cole et al., 2004, 2006;
Uchida et al., 2005, 2009; Yoshimura et al., 2005; Hou et al.,
2009). Specifically, GSK3β phosphorylates CRMP2 at threonines
509, 514, and serine 518, thereby reducing its affinity for tubulin
(Yoshimura et al., 2005). As inactivation of GSK3β is observed
following TLE-related insults, it is possible that these insults
may also lead to a decrease in GSK3β-phosphorylated (inactive)
CRMP2, thereby promoting outgrowth. Indeed we have recently
demonstrated that targeting CRMP2 with (R)-LCM can pre-
vent the increased excitatory connectivity of layer V pyramidal
neurons in the neocortical isolation (undercut) model of post-
traumatic epileptogenesis (Wilson et al., 2012b). Therefore, if loss
of CRMP2 phosphorylation is a contributing factor in mossy
fiber sprouting, it may be possible to prevent this reorganization
through the use of (R)-LCM and its derivatives. In this report we
determine if GSK3β phosphorylation of CRMP2 is altered at var-
ious stages following a TLE-related insult, as well as, the impact
of GSK3β inactivation on CRMP2 function. Ultimately, the role
of CRMP2 in mossy fiber sprouting is investigated by selectively
targeting CRMP2 function in vivo.
Lacosamide was originally discovered to be stereoselective, as
much higher concentrations of the (S)- configuration are required
to halt epileptiform activity both in vitro and in vivo compared
to the (R)- configuration (Andurkar et al., 1999; LeTiran et al.,
2001; Lees et al., 2006). In this report we employ the use of
(S)-LCM, which retains the ability to target CRMP2-mediated
neurite outgrowth without impacting sodium channel function,
to determine if GSK3β phosphorylation of CRMP2 is altered at
various stages following a TLE-related insult. Ultimately, the role
of CRMP2 in mossy fiber sprouting is investigated by selectively
targeting CRMP2 function in vivo.
MATERIALS AND METHODS
MATERIALS
All reagents were purchased from Sigma (St. Louis, MO, USA)
unless otherwise indicated. (S)-LCM was provided by the lab-
oratory of Dr. Ki Duk Park, Center for Neuro-Medicine, Brain
Science Institute, Korea Institute of Science and Technology. A
100mM solution was made up in dimethylsulfoxide (DMSO)
and stored in small aliquots at −20◦C. The final concentration
of 200μM was chosen as it phenocopied the effect of CRMP2
siRNA knockdown (data not shown).
CORTICAL NEURON CULTURE
Rat cortical neuron cultures were prepared from cortices dis-
sected from embryonic day 19 (E19) rats as described (Goslin
and Banker, 1989), with some modifications. Briefly, cortices
were dissected out of E19 rats, and cells were dissociated
enzymatically and mechanically (trituration through Pasteur
pipette) in a Papain solution (12U/ml; Worthington) contain-
ing Leibovitz’s L-15 medium (Invitrogen), 0.42mg/ml cysteine
(Sigma), 250U/ml DNase 1 (type IV; Sigma), 25mM NaHCO3,
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penicillin (50 U/ml)/streptomycin (50μg/ml), 1mM sodium
pyruvate, and 1mg/ml glucose (Invitrogen). After dissociation,
the cells were gently washed by sequential centrifugation in
Neurobasal medium containing either 2mg/ml or 20mg/ml
BSA and Pen/Strep, glucose, pyruvate, and DNase1 (as above)
and then plated on poly-D-lysine-coated coverslips or 96-well
plates at ∼400 cells per mm2. Growth media (1ml/well or
100μl/well for 12- and 96-well plates, respecitvely) consisted
of Neurobasal medium continaing 2% NuSerum, 2% NS21
(Chen et al., 2008), supplemented with penicillin/streptomycin
(100U/ml; 50μg/ml), 0.1mM L-Glutamine and 0.4mML-
glutamax (Invitrogen). 5-fluoro-2′-deoxyuridine (1.5μg/mL)
(Sigma) was added 48 h after plating to reduce the number of
non-neuronal cells. After 4 days in culture and 2× each week
thereon, half of the growth medium was replaced with medium
without 5-fluoro-2′-deoxyuridine.
NEURITE OUTGROWTH
Primary cortical neurons plated on 96-well culture plates were
transfected via lipofectamine 2000 (Invitrogen) with EGFP
at 4DIV 48 h before imaging with the ImageXpress Micro
(Molecular Devices). Immediately prior to imaging, media was
exchanged with sterile phosphate buffered saline (PBS). The over-
expression of EGFP allowed for visualization of a small percentage
of neurons while maintaining optimal cell densities required for
survival. EGFP fluorescence was imaged at 4× magnification. To
enable laser-based autofocus, laser offset was determined via z-
stack. Optimum exposure time was also determined to prevent
saturation.
Analysis of neurite outgrowth was completed using a neu-
rite outgrowth analysis protocol within the MetaXpress software
(Molecular Devices). Cell soma and processes are detected by
defining separate size and fluorescence intensity threshold param-
eters. Cells were excluded if they were determined not to be
neurons based on morphology, if processes extended beyond the
image field, or if no processes were longer than 50μm. The fol-
lowing parameters are recorded and summarized into a final
“total outgrowth” parameter: number of processes, number of
branches, mean process length, and maximum process length.
WHOLE-CELL PATCH-CLAMP RECORDINGS
Whole-cell voltage recordings were performed at RT on primary
cultured cortical neurons (7DIV) using an EPC 10 Amplifier
(HEKA Electronics). Electrodes were pulled from thin-walled
borosilicate glass capillaries (Warner Instruments) with a P-97
electrode puller (Sutter Instrument) such that the final electrode
resistances were 2–3 M when filled with internal solutions. The
internal solution for recording Na+ currents contained (in mM):
110 CsCl, 5 MgSO4, 10 EGTA, 4 ATPNa2, and 25 HEPES (pH 7.2,
290–310mOsmo/L). For recording Na+ currents, the external
solution contained (in mM): 100 NaCl, 10 tetraethylammonium
chloride (TEA-Cl), 1 CaCl2, 1 CdCl2., 1 MgCl2, 10 D-glucose, 4
4-AP, 0.1 NiCl2, 10 HEPES (pH 7.3, 310–315 mOsm/L). Whole-
cell capacitance and series resistance (70–80%) were compensated
with the amplifier. Cells were considered only when the seal resis-
tance was more than 1 G and the series resistance was less than
10 M. Linear leak currents were digitally subtracted by P/4.
IMMUNOBLOT ASSAY AND QUANTIFICATION
Protein samples were boiled in Laemmli sample buffer for
5min and fractionated on 4–15% separating SDS polyacry-
lamide gels. Apparent molecular weights were determined using
broad range standards (Fisher). Following electrophoresis, pro-
teins were transferred to PVDF membranes (Invitrogen) for
immunoblotting. Membranes were occasionally stained with
ponceau (BioRad) to monitor transfer efficiency. Following
transfer, membranes were blocked for 1 h in 5% skim milk
powder +0.05% BSA in TBST at RT. Primary antibody incu-
bations [goat anti-rabbit GSK3β and GSK3β pSer9 (Millipore),
goat anti-rabbit CRMP2 (Sigma), donkey anti-sheep CRMP2
pThr509/514 (Kinasource), goat-anti-rabbit CRMP2 pSer522
(ECM Biosciences), goat anti-rabbit CDK5 (Cell Signaling), or
goat anti-mouse βIII-tubulin (Promega)] were either 2 h at RT
or overnight at 4◦C. Membranes were extensively washed in
TBST and incubated in secondary antibody [goat anti-rabbit,
goat anti-mouse, or donkey anti-sheep IgG horseradish perox-
idase (HRP)] (G Biosciences) or (goat anti-rabbit, goat anti-
mouse IgG dylight 650 or 800 conjugated) (Pierce) (1:15,000).
Membranes incubated with HRP-conjugated secondary anti-
bodies were washed extensively in TBST prior to probing
with Enhanced Chemiluminescence Western blotting substrate
(Fisher) before exposure to photographic film. Blots were exposed
for a range of durations to ensure the generation of a print
in which the film is not saturated. Membranes incubated with
dylight-conjugated secondary antibodies were washed extensively
in TBST prior to imaging with the LI-COR Odyssey imaging
system. Both images obtained from film and LI-COR were digi-
tized and quantified using Un-Scan-It gel V6.1 scanning software
(Silk Scientific Inc., Orem), limiting our analysis to the linear
range. Immunoblot images were digitized and analyzed using
UnscanIt software, limiting analysis to the digital range. Briefly,
densitometric values were obtained for each band and normal-
ized to a loading control (tubulin) for each respective sample. In
place of a single backgroundmeasurement, background values for
each band were obtained from an directly adjacent area to avoid
issues of background discrepancy. To better allow for direct com-
parisons, measurements for CDK5- and GSK3β-phosphorylated
CRMP2 were compared to values for total CRMP2 and Tubulin
from the same immunoblot following a stripping and reprob-
ing procedure. The same method was also applied for comparing
phosphorylated-GSK3 to total GSK3 and tubulin. While this
method provides a direct comparison between levels of each pro-
tein within a single, loaded sample, the stripping procedure does
decrease the esthetic quality of the immunoblot.
TRAUMATIC BRAIN INJURY
All procedures involving animals were approved by the
Institutional Animal Care and Use Committee of Indiana
University School of Medicine and were carried out according
to NIH guidelines and regulations. Animals were doubly-housed
and maintained in a 12 h light/12 h dark cycle environment with
access to foor and water ad libitum. Adult male Sprague–Dawley
rats (275–300 g) were subjected to controlled cortical impact
(CCI) injury. Rats were anesthetized with a ketamine/xylazine
mixture (80 and 5mg/kg, respectively) and placed in a stereotaxic
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frame prior to TBI. Using sterile procedures, the skin was
retracted, and a ∼4mm craniotomy was performed ∼3mm
lateral to midline and 3mm posterior to the bregma suture.
The skullcap was removed without disruption of the dura. The
impacting tip was angled on a medial-lateral plane so that it was
perpendicular to the exposed cortical surface. The deformation
impact depth was set a 1.5mm, and the piston velocity was con-
trolled at 3.0 m/s. Following impact, the exposed tissue was cov-
ered with bone wax (Henry Schein) and the midline incision was
sutured with 5.0 monofilament (Ethicon). Following surgery, ani-
mals received a bolus of sterile saline and post-operative analgesic
Buprenorphine (0.5mg/kg). During all surgical procedures and
recovery, the core body temperature of the animals were main-
tained at 36–37◦C. Sham animals received the same craniotomy
and post-operative care.
IN VIVO ADMINISTRATION OF (S)-LACOSAMIDE ((S)-LCM)
To provide continuous infusion, (S)-LCM was delivered via an
implanted osmotic mini-pump (Alzet). To compensate for ani-
mal growth over the 4-week treatment period, the animals were
weighed prior to surgery and the amount of (S)-LCM was
adjusted to account for the expected weight gain and an infu-
sion rate of 2.5μl/h to allow for administration of an average
of 5mg/kg per day of (S)-LCM or <0.01% DMSO for vehi-
cle. Immediately following CCI surgery, sterile mini-pumps were
subcutaneously implanted. An incision was made on the back,
between the shoulder blades. A small pocket was created by care-
fully separating skin from muscle near the incision site. The
mini-pumpwas placed into the pocket and the incision was closed
with 5.0 monofilament.
TISSUE PROCESSING
For immunoblots: at 24 h or 4 weeks post-TBI, animals were sac-
rificed and transcardially perfused with 0.1M phosphate buffer.
For perfusion, an incision is made in the left ventricle to allow
insertion of a needle attached to a peristaltic pump through the
ventricle and into the ascending aorta. The needle was clamped
into position and a second incision was made in the right atrium
for drainage. Following perfusion, brains were extracted and
hippocampi ipsilateral and contralateral to the injury site were
dissected, frozen in liquid nitrogen, and stored at −80◦C. Prior to
immunoblot assay, tissue was thawed and homogenized using a
sonicator.
For TIMM staining: at 4 weeks following TBI, animals were
sacrificed and transcardially perfused (as previously described)
with a sodium sulfide perfusate solution (150mM NaS2, 8.1mM
Na2HPO4, 1.9mM NaH2PO4), followed by 4% paraformalde-
hyde. Following perfusion, brains were extracted and placed in
4% paraformaldehyde for 24 h at 4◦C. Brains were then trans-
ferred to 0.1M phosphate buffer + 30% sucrose for 48 h at 4◦C.
Tissue was embedded into Optimal Cutting Temperature (OCT)
compound (Tissue-Tek) on dry ice. Coronal slices (35μm thick-
ness) were made on a cryostat (Leica). Slices were mounted onto
gelatin-coated microscope slides and stored at −20◦C.
TIMM STAINING
Tissue sections were allowed to thawed and processed for
TIMM staining with the RAPID TIMM Stain Kit (FD
Neurotechnologies). Tissue sections were washed in 0.1M
phosphate buffer 3 times, 3min each and transferred to the
TIMM solution (132mM Citric Acid, 79.5mM Sodium Citrate,
153.6mM Hydroquinone, 5mM AgNO3, 30% Gum Arabic),
where they were rocked gently in the dark for 45–60min at 30◦C.
Sections were then rinsed in ddH2O for 3min in the dark, fol-
lowed by gently washing them in running water for 30min to
remove excess stain. Sections were dehydrated in 50, 75, and
95% ethanol for 3min each. Sections were incubated in absolute
ethanol 3 times, 3min each and then cleared in xylene (Fisher)
3 times, 3min each. Coverslips were added using a resinous
mounting medium (Aquamount) (Fisher).
Both low and higher magnification images were obtained
using a light microscope (Nikon 90i) and scored by three
observers blinded to the conditions, based on the scale origi-
nally established by Cavazos et al. (1991). Briefly, the scoring
system ranks TIMM staining on a scale of 0–5, with 0 being
the absence of TIMM granules within the supragranular region
and 5 indicating the existence of a dense band of TIMM gran-
ules within the supragranular region, extending into the inner
molecular layer. To avoid issues of variance among animals, scores
were compared from contralateral and ipsilateral hippocampi
from the same animal to yield the difference in TIMM scoring
(Ispilateral—Contralateral).
DATA ANALYSIS
All data points are shown as mean ± s.e.m. Statistical differences
between control and experimental conditions were determined
by using ANOVA with a Dunnett’s or Tukey’s post-hoc test or a
Student’s t-test when comparing only two conditions. Values of
p < 0.05 were judged to be statistically significant.
RESULTS
In regards to its outgrowth-promoting function, the activity
of CRMP2 is regulated by its phosphorylation state. In the
unphosphorylated form, CRMP2 is considered active and thereby
growth-promoting; however, upon phosphorylation by a vari-
ety of kinases, most notably GSK3β, CRMP2 is rendered inactive
(Arimura et al., 2000, 2005; Brown et al., 2004; Cole et al., 2004,
2006; Uchida et al., 2005, 2009; Yoshimura et al., 2005; Hou et al.,
2009). Tonically active under naïve conditions, GSK3β is inacti-
vated following insults commonly associated with TLE such as
TBI (Shapira et al., 2007; Dash et al., 2011; Zhao et al., 2012),
hypoxia-ischemia (Sasaki et al., 2001; Endo et al., 2006; Xiong
et al., 2012), and SE (Lee et al., 2012). This inactivation of GSK3β
may lead to an overall decrease in the level of phosphorylated
(inactive) CRMP2, thereby promoting neurite outgrowth.
GSK3β PHOSPHORYLATION OF CRMP2 UNDER NAïVE CONDITIONS
In order for inactivation of GSK3β to impact CRMP2 func-
tion, a proportion of CRMP2 must be phosphorylated by GSK3β
under normal conditions. Additionally, changes in CRMP2 phos-
phorylation by GSK3β should occur on a relatively fast time-
scale. To determine the extent of GSK3β phosphorylation of
CRMP2, primary cultured cortical neurons were exposed to
the GSK3β inhibitor Lithium Chloride (LiCl) (10mM) or the
protein phosphatase inhibitor okadaic acid (200 nM) for 18–
24 h (Figure 1A). Western blot analysis was performed with
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FIGURE 1 | Phosphorylation of CRMP2 by GSKβ. (A) Signaling cascade
involved in changes in phosphorylation of CRMP2 by GSK3β. Inactivation of
GSK3β occurs following activation of Akt or exogenous exposures to lithium
chloride (LiCl). Dephosphorylation of CRMP2 by PP2A is prevented by
exposure to okadaic acid (OA). (B) Levels of GSK3β-phosphorylated CRMP2
and total CRMP2 following 24 h treatment with LiCl (10mM) or OA (200 nM).
(C,D) Summary of western blot analysis of GSK3β-phosphorylated CRMP2
and total CRMP2 levels in cortical neurons ± LiCl or OA (∗p < 0.05 vs. Ctrl,
One-Way ANOVA, Dunnet’s post-hoc analysis) (values represent mean ±
s.e.m.) (n = 3).
an antibody specific to GSK3β-mediated phosphorylation of
CRMP2 at Thr509 and Thr514. Importantly, CRMP2 appears
to be phosphorylated by GSK3β under naïve/control conditions
(Figures 1B,C). Prevention of dephosphorylation by okadaic acid
increased CRMP2 phosphorylation by∼2-fold (12.1 ± 1.3) com-
pared to control (6.6 ± 0.6), while LiCl-mediated inhibition of
GSK3β resulted in an ∼90% loss of CRMP2 phosphorylation
(0.6 ± 0.3) (p < 0.05) (Figures 1B,C). Levels of total CRMP2
protein remained unchanged (control: 0.31 ± 0.03; okadaic acid:
0.41 ± 0.05; and LiCl: 0.37 ± 0.03) (p > 0.05) (Figure 1D). This
data suggests that a proportion of CRMP2 is phosphorylated
by GSK3β under normal conditions and loss of GSK3β activ-
ity dramatically dramatically results in a near-complete loss of
phosphorylated CRMP2 within 18–24 h. GSK3β phosphorylation
of CRMP2 appears to be dynamically regulated, as evidenced by
active dephosphorylation under control conditions.
GSK3β INHIBITION INCREASES NEURITE OUTGROWTH VIA CRMP2
In regards to its ability to promote neurite outgrowth, phospho-
rylation by GSK3β effectively inactivates CRMP2 by reducing its
affinity for tubulin (Yoshimura et al., 2005). Therefore, inacti-
vation of GSK3β should be growth promoting. To determine if
the LiCl-induced loss of GSK3β-phosphorylated CRMP2 directly
alters CRMP2-mediated neurite outgrowth within the same
timeframe, EGFP-transfected cortical neurons were exposed to
lithium chloride for 18–24 h to determine the effect of GSK3β
inhibition on neurite outgrowth (Figure 2A). Immediately fol-
lowing exposure, neurons were imaged using the ImageXpress
Micro system and neurite outgrowth was determined via the
MetaXpress software system. As expected, inhibition of GSK3β
increased total outgrowth (154.5 ± 5.9) compared to controls
(99.8 ± 4.0) (p < 0.05) (Figures 2B–D). We had previously
demonstrated that (S)-LCM, the inactive enantiomer of (R)-
LCM, retains the ability to target CRMP2 function and can
therefore be used in place of knockdown strategies to determine
the role of CRMP2 in a particular process (Wilson and Khanna,
unpublished). To ensure that the LiCl-induced increase in out-
growth was in fact due to changes in CRMP2 activity, the exper-
iment was repeated in the presence of (S)-LCM (200μM). As
(S)-LCM alone decreases outgrowth, it was included in both LiCl-
treated and control conditions. Without (S)-LCM, LiCl increased
neurite outgrowth by 54.9 ± 5.9% (Figure 2D). In contrast, in
the presence of (S)-LCM, LiCl increased neurite outgrowth by
15.3 ± 5.1% (p < 0.05) (Figures 2D,E).
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FIGURE 2 | Inactivation of GSK3β enhances neurite outgrowth in a
CRMP2-dependent manner. (A) Experimental timeline. Cortical neurons
were transfected with EGFP at 4DIV and exposed to vehicle (<0.01%
DMSO), LiCl (10mM), (S)-LCM (200μM), or LiCl + (S)-LCM for 24 h starting
at 5DIV and imaged at 6DIV. (B) GSK3β signaling cascade. (C)
Representative tracings of neurons transfected with EGFP and exposed to
LiCl, (S)-LCM, or both. (Scale bar = 150μm). (D) Total outgrowth of neurons
exposed to LiCl for 24 h (∗p < 0.05, student’s t-test) (values represent
mean ± s.e.m.). (E) Enhancement of outgrowth by LiCl under conditions of
(S)-LCM treatment (∗p < 0.05 vs. EGFP, One-Way ANOVA, Dunnet’s post-hoc
analysis) (values represent mean ± s.e.m.) (n = 92–150 cells from 8 separate
culture wells).
(S)-LCM DOES NOT TARGET VOLTAGE-GATED SODIUM CHANNELS
It is essential to verify that (S)-LCM is unable to impact voltage-
gated sodium channels in this system. Therefore, sodium channel
slow inactivation of cultured cortical neurons was determined
by holding cells at −70mV, conditioning to potentials ranging
from −100 to +20mV (in +10mV increments) for 5 s, moved
to a hyperpolarizing pulse of −120mV for 150ms to allow
fast-inactivated channels to recover, and a single depolarizing
pulse to 0mV was applied for 15ms to determine the frac-
tion of channels available (Figure 3A). The addition of 200μM
(S)-LCM did not alter the onset or extent of slow inactiva-
tion (Figures 3B–D). We next determined the effect of (S)-LCM
on fast inactivation and steady-state activation. For fast inac-
tivation, cells were held at −80mV, conditioned to potentials
ranging from −120 to −10mV (in +10mV increments) for
500ms and the fraction of available current was determined by
a 20ms test pulse at 0mV (Figure 3E). For steady-state activa-
tion, cells were held at −80mV and current was measured at
potentials ranging from−70 to+80mV (in+10mV increments)
for 500ms (Figure 3E). Neither fast inactivation nor steady-state
inactivation was effected by (S)-LCM (Figure 3F).
LOSS OF CRMP2 PHOSPHORYLATION FOLLOWING TBI
The development of TLE following TBI, accounts for 20%
of symptomatic epilepsy (Agrawal et al., 2006). Evidence of
increased Akt activation within the hippocampus as well as other
regions has been observed following TBI (Zhang et al., 2006;
Zhao et al., 2012). Corresponding to changes in Akt activity, levels
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of phosphorylated (inactive) GSK3β are also increased following
TBI (Shapira et al., 2007; Dash et al., 2011; Zhao et al., 2012).
To determine if changes in CRMP2 phosphorylation could be
the driving force behind the increased neurite outgrowth in the
hippocampus following TLE-related insults, hippocampal tissue
was collected at both early (24 h) and late (4 weeks) phases fol-
lowing TBI in adult male rats. Consistent with previous reports,
levels of Ser9-phosphorylated (inactivated) GSK3βwere increased
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in the early phase following TBI (1.31 ± 0.08) compared to sham
controls (1.00 ± 0.05) (p < 0.05) (Figures 4A,B). Importantly,
total expression of GSK3β remained unchanged [(1.00 ± 0.11) vs.
(0.81 ± 0.12)] (p > 0.05) (Figures 4A,B). The increase in GSK3β
phosphorylation appeared to be transient, as levels did not dif-
fer at 4 weeks following TBI (0.97 ± 0.12) compared to sham
controls (1.00 ± 0.06) (p > 0.05) (Figures 4C,D).
Subsequent to the observed inactivation of GSK3β, levels of
GSK3β-phosphorylated CRMP2 were reduced in the early phase
following TBI (0.52 ± 0.07) compared to sham controls (1.00 ±
0.13) (p < 0.05) (Figures 5A,B). No change in total CRMP2
expression was observed [(1.10 ± 0.12) vs. (1.00 ± 0.04)] (p >
0.05) (Figures 5A,B). Despite the observed transience of GSK3β
inactivation, levels of GSK3β-phosphorylated CRMP2 remained
reduced in the late phase following TBI (0.62 ± 0.08) compared
to sham controls (1.00 ± 0.09) (p < 0.05) (Figures 5C,D). These
results suggest that there is an increased level of active (unphos-
phorylated) CRMP2 in both the early and late phases following
TBI. Interestingly, while the decrease in CRMP2 phosphoryla-
tion at 24 h post-TBI is directly correlated with an inactivation
of GSK3β, the sustained decrease observed at 4 weeks post-TBI
appears to be independent of changes in GSK3β activity.
“PRIMED” CRMP2 IS DECREASED IN THE LATE, BUT NOT EARLY PHASE
FOLLOWING TBI
Phosphorylation of GSK3β is not the only avenue through which
phosphorylation of its substrates is regulated. GSK3β substrate
recognition can be complex, as there is no strict consensus
motif, often requiring prior phosphorylation (priming) at a ser-
ine slightly c-terminal to the GSK3β site(s) (DePaoli-Roach,
1984; Fiol et al., 1988). This type of hierarchical phosphoryla-
tion allows for complex regulation at multiple levels. In the case of
CRMP2, it must first be phosphorylated at serine 522 by the ser-
ine/threonine kinase cyclin-dependent protein kinase 5 (CDK5)
in order to be phosphorylated by GSK3β (Yoshimura et al., 2005;
Cole et al., 2006) (Figure 6A). Sequential phosphorylation of
CRMP2 by CDK5 and GSK3β has been demonstrated for many
facets of CRMP2 function, most importantly, neurite outgrowth
and growth cone collapse (Brown et al., 2004; Uchida et al.,
2005). As decreased levels of GSK3β-phosphorylated CRMP2
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Frontiers in Cellular Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 135 | 8
Wilson et al. Targeting CRMP2 in traumatic brain injury
CRMP2 pThr509/514 CRMP2
0.0
0.5
1.0
1.5
A.
D.
U.
(N
or
m
al
ize
d 
to
 S
ha
m
)
 Sham
 TBI
CRMP2 pThr509/514 CRMP2
0.0
0.5
1.0
1.5
A.
D.
U.
(N
or
m
al
ize
d 
to
 S
ha
m
)
 Sham
 TBI
*
*
CRMP2 
pThr509/514
CRMP2
Tubulin
Sham TBI
CRMP2 
pThr509/514
CRMP2
Tubulin
Sham TBI
67 kDa
67 kDa
52 kDa
67 kDa
67 kDa
52 kDa
BA
DC
24 hr post-TBI
4 wk post-TBI
FIGURE 5 | Changes in CRMP2 phosphorylation by GSK3β following
TBI. (A) Western blots of GSK3β-phosphorylated and total CRMP2 from
hippocampal tissue 24 h following TBI. (B) Summary of CRMP2
pThr509/514 and total CRMP2 levels 24 h following TBI (raw data
represents protein of interest normalized to tubulin and further normalized
to sham to allow for easy comparison) [data is represented as arbitrary
densitometric units (A.D.U)]. (C) Western blots of GSK3β-phosphorylated
and total CRMP2 from hippocampal tissue 4 weeks following TBI. (D)
Summary of CRMP2 pThr509/514 and total CRMP2 levels 4 weeks
following TBI. Data was normalized to sham conditions for ease of
comparison. (∗p < 0.05 vs. sham, Student’s t-test) (values represent
mean ± s.e.m. from n = 4–5).
were observed in the late phase following TBI that were not
secondary to changes in GSK3β expression or activity, it is
possible that the changes in levels of GSK3β-phosphorylated
CRMP2 may be attributed to a decrease in phosphorylation by
CDK5. Therefore, levels of CDK5-phosphorylated CRMP2 were
determined from hippocampal tissue collected at early (24 h)
and late (4 weeks) time points following TBI. Notably, CDK5
phosphorylation of CRMP2 at 24 h following TBI did not dif-
fer from sham controls [(1.05 ± 0.07) vs. (1.00 ± 0.12)] (p >
0.05) (Figures 6B,C). However, at 4 weeks following injury, lev-
els of CDK5-phosphorylated CRMP2 were decreased (0.69 ±
0.07) compared to sham controls (1.00 ± 0.03) (p < 0.05)
(Figures 6B,C). These results suggest that CRMP2 is differen-
tially regulated during early and late phases following injury.
While a loss of GSK3β activity accounts for decreases in CRMP2
phosphorylation immediately following injury, the same phe-
notype during later phases is attributed to a loss of priming
by CDK5.
EFFECTS OF TARGETING CRMP2 IN VIVO ONMOSSY FIBER SPROUTING
As changes in CRMP2 phosphorylation, and presumably activ-
ity, are observed within the hippocampus at both early and late
time points following TBI, CRMP2 may be involved in both the
induction and maintenance of mossy fiber sprouting following
injury. To determine the importance of CRMP2 in this phe-
nomenon, osmotic minipumps containing (S)-LCM (140mg/kg)
were implanted (subcutaneously) immediately following TBI
surgery in adult male rats. This method allowed for continuous
delivery of ∼5mg/kg (S)-LCM per day (∼0.21mg/kg per hour)
over the course of 4 weeks (Figure 7A). The extent of aberrant
mossy fiber sprouting is easily identified due to the high amount
of chelatable zinc within mossy fibers which can be visualized via
a silver-sulfide staining method (TIMM staining) (Timm, 1958;
Zimmer, 1973). Therefore, at the cessation of treatment, bilateral
hippocampal tissue was obtained and processed for TIMM stain-
ing, to reveal the extent of mossy fiber sprouting within the inner
molecular layer of the hippocampus.
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As expected, TBI led to increased TIMM differences (1.40 ±
0.25) compared to sham controls (0.25 ± 0.25) (p < 0.05)
(Figures 7B–D). Importantly, differences in TIMM scores did not
differ between sham (0.25 ± 0.25) and naïve animals (0.00 ±
0.32) (p > 0.05). Intriguingly, (S)-LCM treatment prevented the
TBI-induced increase in TIMM differences (0.40 ± 0.25) com-
pared to animals receiving TBI alone (1.40 ± 0.25) (p < 0.05)
(Figures 7B–D). However, the changes in TIMM scores fol-
lowing TBI did not differ between animals receiving (S)-LCM
(0.40 ± 0.25) and vehicle (∼0.01%DMSO) (1.00 ± 0.00) (p >
0.05) (Figures 7C–D). Therefore, it cannot definitively be con-
cluded that CRMP2 is necessary for mossy fiber sprouting
following TBI.
DISCUSSION
In order for changes in GSK3β activity to impact CRMP2 func-
tion, a balance of GSK3β-phosphorylated and unphosphorylated
CRMP2 must be present. Importantly, GSK3β phosphoryla-
tion of CRMP2 appears to be dynamically regulated in naïve
neurons, as inhibition of GSK3β led to an almost complete
loss of phosphorylation within 24 h. Additionally, the increase
in phosphorylation following okadaic acid exposure provides
evidence for active dephosphorylation. Therefore, changes in
GSK3β activity can directly impact CRMP2 function. Indeed,
inhibition of GSK3β led to increases in neurite outgrowth in a
CRMP2-dependent manner. Given that inactivation of GSK3β
has previously been demonstrated following TBI, decreased phos-
phorylation of CRMP2 may account for the changes in neurite
elongation and branching observed within the hippocampus.
Our findings indicate that TBI leads to decreased GSK3β phos-
phorylation of CRMP2 at both 24 h and 4 weeks post-injury.
As mossy fiber sprouting is considered a progressive process,
the maintained loss of phosphorylation throughout later phases
following injury is an important finding. In contrast to early
phases following TBI, the loss of GSK3β phosphorylation at 4
weeks post-injury is likely not attributed to a prolonged inac-
tivation of GSK3β. In fact, previous reports suggest that levels
of Akt-phosphorylated GSK3β return to baseline within 14 days
(Dash et al., 2011). These findings suggest that while CRMP2
may play an integral role in promoting neurite outgrowth both
immediately following injury as well as in later phases, the
mechanisms underlying the increase in CRMP2 activity during
these phases may differ. Indeed, our results revealed that the
decrease in GSK3β-phosphorylated CRMP2 during later phases
following injury was in fact attributed to a decrease in priming
by CDK5.
Mossy fiber sprouting in TLE can likely be divided into 2 dis-
tinct phases: the induction phase, during which sprouting and
outgrowth are attributed directly to the precipitating insult such
as TBI, hypoxia-ischemia, or SE, and the maintenance phase
(Sutula, 2004; Pitkänen and Lukasiuk, 2009). Therefore, early
events following injury, such as inactivation of GSK3β, can be
attributed to injury-induced mechanisms (i.e., activation of pro-
survival signaling pathways). The latter phase involves processes
secondary to the original insult such as hyperexcitability and net-
work synchronization. Interestingly, we have previously demon-
strated that CDK5 priming of CRMP2 is decreased in response
to prolonged neuronal activity and that the loss of priming is
directly translated into a reduction in GSK3β-phosphorylated
CRMP2 (Wilson and Khanna, unpublished). As TBI can lead to
progressive hyperexcitability (Yang et al., 2010b), the sustained
loss of CRMP2 phosphorylation is potentially due to progres-
sive changes in neuronal function which are secondary to the
precipitating injury, such as activity-driven changes in CDK5
function.
Overall, phosphorylation of CRMP2 appears to be differen-
tially regulated through both induction (early) and maintenance
(late) phases following TBI. As such, targeting CRMP2-mediated
neurite outgrowth throughout these stages may be sufficient to
attenuate the progression of mossy fiber sprouting. Indeed, the
extent of mossy fiber sprouting in animals that had received con-
tinuous administration of (S)-LCM following TBI was markedly
decreased compared to untreated animals. However, the trend-
ing effect of vehicle administration is a confounding factor that
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prevents a definitive conclusion from being drawn. Changes in
hippocampal cell death likely do not account for the observed
changes in TIMM staining, as dentate granule cell survival is typ-
ically not impacted by moderate TBI (Lowenstein et al., 1992;
Grady et al., 2003). Furthermore, (S)-LCM is unlikely to affect
hippocampal cell death as a recent study demonstrated that the
parent compound (R)-LCM does not alter neuronal survival
following TBI (Pitkanen et al., 2014). The lack of significant sep-
aration between (S)-LCM- and vehicle-treated groups may be a
result of the nature of administration, despite the previous suc-
cess observed with infusion of (R)-LCM in a separate study (Licko
et al., 2013). While continuous subcutaneous infusion was con-
sidered to be preferable over daily intraperitoneal injections, it is
possible that inflammation at the implantation site may have been
a factor.
Although the exact role of CRMP2 in mossy fiber sprouting
has not yet been determined, it is possible that the loss of GSK3β
phosphorylation immediately following injury contributes to the
induction of mossy fiber sprouting while the loss of priming by
CDK5 in later phases contributes to the maintenance of mossy
fiber sprouting. It is of great interest that these mechanistically
distinct events culminate in a similar end-point: an increase in
the amount of active CRMP2 (Figure 8). The reduction in mossy
fiber sprouting in (S)-LCM-treated animals suggests, at the very
least, that CRMP2 may be one factor involved in initiation and
progression of mossy fiber sprouting.
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(inactive) CRMP2. (B) CDK5 phosphorylation of CRMP2 is decreased in
the later phases following injury. This decrease in phosphorylation also
indirectly reduces levels of GSK3β-phosphorylated CRMP2 through a loss
of priming, resulting in an overall increase in the proportion of active
CRMP2. (C) Despite the sustained increase in unphosphorylated (active)
CRMP2 in the hippocampus, the role of CRMP2 in aberrant mossy fiber
sprouting following injury remains unclear, as denoted by the “?.”
AUTHORS AND CONTRIBUTORS
Participated in Research Design—Sarah M. Wilson, Rajesh
Khanna. Conducted Experiments—Sarah M. Wilson, Seul Ki
Yeon, Xiao-Fang Yang. Performed Data Analysis—Sarah M.
Wilson, Seul Ki Yeon, Ki Duk Park, Xiao-Fang Yang. Wrote the
Manuscript—Sarah M. Wilson, Rajesh Khanna.
ACKNOWLEDGMENTS
We thank Dr. Weina Ju for help with some of the immunoblots,
and members of the Stark Neurosciences Research Institute for
helpful comments and discussions. We express many thanks
to Dr. Fletcher White and Matthew Ripsch for their generous
guidance in experimental design, as well as, the use of their equip-
ment. This work was supported, in part, by a grant a National
Scientist Development from the American Heart Association
(SDG5280023 to Rajesh Khanna) and a grant from the Showalter
foundation (to Rajesh Khanna). Sarah M. Wilson was par-
tially funded by a Stark Fellowship and a Larry Kays Medical
Neuroscience award.
REFERENCES
Agrawal, A., Timothy, J., Pandit, L., and Manju, M. (2006). Post-traumatic
epilepsy: an overview. Clin. Neurol. Neurosurg. 108, 433–439. doi:
10.1016/j.clineuro.2005.09.001
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., et al.
(1996). Mechanism of activation of protein kinase B by insulin and IGF-1.
EMBO J. 15, 6541–6551.
Andersen, P., Bliss, T. V., Lomo, T., Olsen, L. I., and Skrede, K. K. (1969). Lamellar
organization of hippocampal excitatory pathways. Acta Physiol. Scand. 76,
4a–5a.
Andurkar, S. V., Stables, J. P., and Kohn, H. (1999). The anticonvulsant activities
of N-benzyl 3-methoxypropionamides. Bioorg. Med. Chem. 7, 2381–2389. doi:
10.1016/S0968-0896(99)00186-8
Arimura, N., Inagaki, N., Chihara, K., Menager, C., Nakamura, N., Amano, M.,
et al. (2000). Phosphorylation of collapsin response mediator protein-2 by Rho-
kinase. Evidence for two separate signaling pathways for growth cone collapse.
J. Biol. Chem. 275, 23973–23980. doi: 10.1074/jbc.M001032200
Arimura, N., Menager, C., Kawano, Y., Yoshimura, T., Kawabata, S., Hattori, A.,
et al. (2005). Phosphorylation by Rho kinase regulates CRMP-2 activity in
growth cones. Mol. Cell Biol. 25, 9973–9984. doi: 10.1128/MCB.25.22.9973-
9984.2005
Beyreuther, B. K., Freitag, J., Heers, C., Krebsfanger, N., Scharfenecker, U., and
Stohr, T. (2007). Lacosamide: a review of preclinical properties. CNS Drug Rev.
13, 21–42. doi: 10.1111/j.1527-3458.2007.00001.x
Bhave, S. V., Ghoda, L., and Hoffman, P. L. (1999). Brain-derived neurotrophic
factor mediates the anti-apoptotic effect of NMDA in cerebellar granule neu-
rons: signal transduction cascades and site of ethanol action. J. Neurosci. 19,
3277–3286.
Blaabjerg, M., and Zimmer, J. (2007). The dentate mossy fibers: structural
organization, development and plasticity. Prog. Brain Res. 163, 85–107. doi:
10.1016/S0079-6123(07)63005-2
Brittain, J. M., Chen, L., Wilson, S. M., Brustovetsky, T., Gao, X., Ashpole, N. M.,
et al. (2011b). Neuroprotection against traumatic brain injury by a peptide
derived from the collapsin response mediator protein 2 (CRMP2). J. Biol. Chem.
286, 37778–37792. doi: 10.1074/jbc.M111.255455
Brittain, J. M., Duarte, D. B., Wilson, S. M., Zhu, W., Ballard, C., Johnson, P. L.,
et al. (2011a). Suppression of inflammatory and neuropathic pain by uncou-
pling CRMP-2 from the presynaptic Ca(2+) channel complex. Nat. Med. 17,
822–829. doi: 10.1038/nm.2345
Brittain, J. M., Pan, R., You, H., Brustovetsky, T., Brustovetsky, N., Zamponi, G. W.,
et al. (2012a). Disruption of NMDAR-CRMP-2 signaling protects against focal
cerebral ischemic damage in the rat middle cerebral artery occlusion model.
Channels (Austin) 6, 52–59. doi: 10.4161/chan.18919
Brittain, J. M., Piekarz, A. D., Wang, Y., Kondo, T., Cummins, T. R., and Khanna, R.
(2009). An atypical role for collapsin response mediator protein 2 (CRMP-2)
Frontiers in Cellular Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 135 | 12
Wilson et al. Targeting CRMP2 in traumatic brain injury
in neurotransmitter release via interaction with presynaptic voltage-gated
calcium channels. J. Biol. Chem. 284, 31375–31390. doi: 10.1074/jbc.M109.
009951
Brittain, J. M., Wang, Y., Eruvwetere, O., and Khanna, R. (2012b). Cdk5-mediated
phosphorylation of CRMP-2 enhances its interaction with CaV2.2. FEBS Lett.
586, 3813–3818. doi: 10.1016/j.febslet.2012.09.022
Brown, M., Jacobs, T., Eickholt, B., Ferrari, G., Teo, M., Monfries, C.,
et al. (2004). Alpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its
target collapsin response mediator protein-2 are essential components in
semaphorin 3A-induced growth-cone collapse. J. Neurosci. 24, 8994–9004. doi:
10.1523/JNEUROSCI.3184-04.2004
Cavazos, J. E., Golarai, G., and Sutula, T. P. (1991). Mossy fiber synaptic reorga-
nization induced by kindling: time course of development, progression, and
permanence. J. Neurosci. 11, 2795–2803.
CDC, CfDCaP. (2012). “Epilepsy in adults and access to care - United States, 2010,”
inMMWR, Vol. 61 (Washington, DC), 909–913.
Chae, Y. C., Lee, S., Heo, K., Ha, S. H., Jung, Y., Kim, J. H., et al. (2009). Collapsin
response mediator protein-2 regulates neurite formation by modulating tubulin
GTPase activity. Cell. Signal. 21, 1818–1826. doi: 10.1016/j.cellsig.2009.07.017
Chen, Y., Stevens, B., Chang, J., Milbrandt, J., Barres, B. A., and Hell, J. W.
(2008). NS21: re-defined and modified supplement B27 for neuronal cultures.
J. Neurosci. Methods 171, 239–247. doi: 10.1016/j.jneumeth.2008.03.013
Cole, A. R., Causeret, F., Yadirgi, G., Hastie, C. J., McLauchlan, H., McManus, E.
J., et al. (2006). Distinct priming kinases contribute to differential regulation
of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo.
J. Biol. Chem. 281, 16591–16598. doi: 10.1074/jbc.M513344200
Cole, A. R., Knebel, A., Morrice, N. A., Robertson, L. A., Irving, A. J., Connolly,
C. N., et al. (2004). GSK-3 phosphorylation of the Alzheimer epitope within
collapsin response mediator proteins regulates axon elongation in primary
neurons. J. Biol. Chem. 279, 50176–50180. doi: 10.1074/jbc.C400412200
Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A.
(1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein
kinase B. Nature 378, 785–789. doi: 10.1038/378785a0
Dash, P. K., Johnson, D., Clark, J., Orsi, S. A., Zhang, M., Zhao, J., et al.
(2011). Involvement of the glycogen synthase kinase-3 signaling pathway in TBI
pathology and neurocognitive outcome. PLoS ONE 6:e24648. doi: 10.1371/jour-
nal.pone.0024648
de Lanerolle, N. C., Kim, J. H., Williamson, A., Spencer, S. S., Zaveri, H. P., Eid,
T., et al. (2003). A retrospective analysis of hippocampal pathology in human
temporal lobe epilepsy: evidence for distinctive patient subcategories. Epilepsia
44, 677–687. doi: 10.1046/j.1528-1157.2003.32701.x
DePaoli-Roach, A. A. (1984). Synergistic phosphorylation and activation of ATP-
Mg-dependent phosphoprotein phosphatase by F A/GSK-3 and casein kinase II
(PC0.7). J. Biol. Chem. 259, 12144–12152.
Dustrude, E. T., Wilson, S. M., Ju, W., Xiao, Y., and Khanna, R. (2013). CRMP2
protein SUMOylationmodulates NaV1.7 channel trafficking. J. Biol. Chem. 288,
24316–24331. doi: 10.1074/jbc.M113.474924
Endo, H., Nito, C., Kamada, H., Nishi, T., and Chan, P. H. (2006). Activation of the
Akt//GSK3[beta] signaling pathway mediates survival of vulnerable hippocam-
pal neurons after transient global cerebral ischemia in rats. J. Cereb. Blood Flow
Metab. 26, 1479–1489. doi: 10.1038/sj.jcbfm.9600303
England, M. J., Liverman, C. T., Schultz, A. M., and Strawbridge, L. M. (2012).
Epilepsy across the spectrum: promoting health and understanding. A summary
of the institute of medicine report. Epilepsy Behav. 25, 266–276. doi: 10.1016/
j.yebeh.2012.06.016
Errington, A. C., Stohr, T., Heers, C., and Lees, G. (2008). The investigational anti-
convulsant lacosamide selectively enhances slow inactivation of voltage-gated
sodium channels.Mol. Pharmacol. 73, 157–169. doi: 10.1124/mol.107.039867
Fiol, C. J., Haseman, J. H., Wang, Y. H., Roach, P. J., Roeske, R. W., Kowalczuk,
M., et al. (1988). Phosphoserine as a recognition determinant for glycogen
synthase kinase-3: phosphorylation of a synthetic peptide based on the G-
component of protein phosphatase-1. Arch. Biochem. Biophys. 267, 797–802.
doi: 10.1016/0003-9861(88)90089-6
Fukata, Y., Itoh, T. J., Kimura, T., Menager, C., Nishimura, T., Shiromizu, T.,
et al. (2002). CRMP-2 binds to tubulin heterodimers to promote microtubule
assembly. Nat. Cell Biol. 4, 583–591. doi: 10.1038/ncb825
Ghasemi, M., and Schachter, S. C. (2011). The NMDA receptor complex as a
therapeutic target in epilepsy: a review. Epilepsy Behav. 22, 617–640. doi:
10.1016/j.yebeh.2011.07.024
Goddard, G. V., McIntyre, D. C., and Leech, C. K. (1969). A permanent change
in brain function resulting from daily electrical stimulation. Exp. Neurol. 25,
295–330. doi: 10.1016/0014-4886(69)90128-9
Goshima, Y., Nakamura, F., Strittmatter, P., and Strittmatter, S. M. (1995).
Collapsin-induced growth cone collapse mediated by an intracellular
protein related to UNC-33. Nature 376, 509–514. doi: 10.1038/37
6509a0
Goslin, K., and Banker, G. (1989). Experimental observations on the development
of polarity by hippocampal neurons in culture. J. Cell Biol. 108, 1507–1516. doi:
10.1083/jcb.108.4.1507
Grady, M. S., Charleston, J. S., Maris, D., Witgen, B. M., and Lifshitz, J. (2003).
Neuronal and glial cell number in the hippocampus after experimental trau-
matic brain injury: analysis by stereological estimation. J. Neurotrauma 20,
929–941. doi: 10.1089/089771503770195786
Hauser, W. A., and Kurland, L. T. (1975). The epidemiology of epilepsy
in Rochester, Minnesota, 1935 through 1967. Epilepsia 16, 1–66. doi:
10.1111/j.1528-1157.1975.tb04721.x
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., and
Zalutsky, R. (2007). How common are the “common” neurologic disorders?
Neurology 68, 326–337. doi: 10.1212/01.wnl.0000252807.38124.a3
Hou, S. T., Jiang, S. X., Aylsworth, A., Ferguson, G., Slinn, J., Hu, H., et al. (2009).
CaMKII phosphorylates collapsin response mediator protein 2 and modulates
axonal damage during glutamate excitotoxicity. J. Neurochem. 111, 870–881.
doi: 10.1111/j.1471-4159.2009.06375.x
Ju, W., Li, Q., Wilson, S. M., Brittain, J. M., Meroueh, L., and Khanna, R. (2013).
SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.
Channels 7, 153–159. doi: 10.4161/chan.24224
Kharatishvili, I., and Pitkanen, A. (2010). Posttraumatic epilepsy. Curr. Opin.
Neurol. 23, 183–188. doi: 10.1097/WCO.0b013e32833749e4
Kimura, T., Watanabe, H., Iwamatsu, A., and Kaibuchi, K. (2005). Tubulin and
CRMP-2 complex is transported via Kinesin-1. J. Neurochem. 93, 1371–1382.
doi: 10.1111/j.1471-4159.2005.03063.x
Koyama, R., and Ikegaya, Y. (2004). Mossy fiber sprouting as a potential therapeu-
tic target for epilepsy. Curr. Neurovasc. Res. 1, 3–10. doi: 10.2174/1567202043
480242
Larner, A. J. (1995). Axonal sprouting and synaptogenesis in temporal lobe
epilepsy: possible pathogenetic and therapeutic roles of neurite growth
inhibitory factors. Seizure 4, 249–258. doi: 10.1016/S1059-1311(95)80001-8
Lee, C.-Y., Jaw, T., Tseng, H.-C., Chen, I. C., and Liou, H.-H. (2012). Lovastatin
modulates glycogen synthase kinase-3β pathway and inhibits mossy fiber
sprouting after pilocarpine-induced status epilepticus. PLoS ONE 7:e38789. doi:
10.1371/journal.pone.0038789
Lees, G., Stohr, T., and Errington, A. C. (2006). Stereoselective effects of
the novel anticonvulsant lacosamide against 4-AP induced epileptiform
activity in rat visual cortex in vitro. Neuropharmacology 50, 98–110. doi:
10.1016/j.neuropharm.2005.08.016
LeTiran, A., Stables, J. P., and Kohn, H. (2001). Functionalized amino acid anti-
convulsants: synthesis and pharmacological evaluation of conformationally
restricted analogues. Bioorg. Med. Chem. 9, 2693–2708. doi: 10.1016/S0968-
0896(01)00204-8
Licko, T., Seeger, N., Zellinger, C., Russmann, V., Matagne, A., and Potschka, H.
(2013). Lacosamide treatment following status epilepticus attenuates neuronal
cell loss and alterations in hippocampal neurogenesis in a rat electrical status
epilepticus model. Epilepsia 54, 1176–1185. doi: 10.1111/epi.12196
Lowenstein, D. H., Thomas, M. J., Smith, D. H., and McIntosh, T. K. (1992).
Selective vulnerability of dentate hilar neurons following traumatic brain injury:
a potential mechanistic link between head trauma and disorders of the hip-
pocampus. J. Neurosci. 12, 4846–4853.
Manford, M., Hart, Y. M., Sander, J. W., and Shorvon, S. D. (1992a). National
General Practice Study of Epilepsy (NGPSE): partial seizure patterns in a general
population. Neurology 42, 1911–1917. doi: 10.1212/WNL.42.10.1911
Manford, M., Hart, Y. M., Sander, J. W., and Shorvon, S. D. (1992b). The national
general practice study of epilepsy. the syndromic classification of the interna-
tional league against epilepsy applied to epilepsy in a general population. Arch.
Neurol. 49, 801–808. doi: 10.1001/archneur.1992.00530320025008
O’Dell, C. M., Das, A., Wallace, G. T., Ray, S. K., and Banik, N. L. (2012).
Understanding the basic mechanisms underlying seizures in mesial temporal
lobe epilepsy and possible therapeutic targets: a review. J. Neurosci. Res. 90,
913–924. doi: 10.1002/jnr.22829
Frontiers in Cellular Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 135 | 13
Wilson et al. Targeting CRMP2 in traumatic brain injury
Oliva, M., Berkovic, S. F., and Petrou, S. (2012). Sodium channels and
the neurobiology of epilepsy. Epilepsia 53, 1849–1859. doi: 10.1111/j.1528-
1167.2012.03631.x
Panayiotopoulos, C. P. (2005). The Epilepsies: Seizures, Syndromes and
Management. Oxfordshire: Bladon Medical Publishing, an imprint of Springer
Science+Business Media.
Park, K. D., Morieux, P., Salome, C., Cotten, S. W., Reamtong, O., Eyers, C.,
et al. (2009). Lacosamide isothiocyanate-based agents: novel agents to tar-
get and identify lacosamide receptors. J. Med. Chem. 52, 6897–6911. doi:
10.1021/jm9012054
Pitkanen, A., Immonen, R., Ndode-Ekane, X., Grohn, O., Stohr, T., and Nissinen,
J. (2014). Effect of lacosamide on structural damage and functional recov-
ery after traumatic brain injury in rats. Epilepsy Res. 108, 653–665. doi:
10.1016/j.eplepsyres.2014.02.001
Pitkänen, A., and Lukasiuk, K. (2009). Molecular and cellular basis of epilepto-
genesis in symptomatic epilepsy. Epilepsy Behav. 14(1 Suppl. 1), 16–25. doi:
10.1016/j.yebeh.2008.09.023
Sasaki, C., Hayashi, T., Zhang, W. R., Warita, H., Manabe, Y., Sakai, K., et al.
(2001). Different expression of glycogen synthase kinase-3beta between young
and old rat brains after transient middle cerebral artery occlusion. Neurol. Res.
23, 588–592. doi: 10.1179/016164101101199054
Shapira, M., Licht, A., Milman, A., Pick, C. G., Shohami, E., and Eldar-Finkelman,
H. (2007). Role of glycogen synthase kinase-3beta in early depressive behavior
induced by mild traumatic brain injury. Mol. Cell. Neurosci. 34, 571–577. doi:
10.1016/j.mcn.2006.12.006
Sharma, A. K., Reams, R. Y., Jordan,W.H.,Miller,M. A., Thacker, H. L., and Snyder,
P. W. (2007). Mesial temporal lobe epilepsy: pathogenesis, induced rodent mod-
els and lesions. Toxicol. Pathol. 35, 984–999. doi: 10.1080/01926230701748305
Siwek, M., Henseler, C., Broich, K., Papazoglou, A., and Weiergraber, M. (2012).
Voltage-gated Ca(2+) channel mediated Ca(2+) influx in epileptogenesis. Adv.
Exp. Med. Biol. 740, 1219–1247. doi: 10.1007/978-94-007-2888-2_55
Sutula, T. P. (2004). Mechanisms of epilepsy progression: current theories and per-
spectives from neuroplasticity in adulthood and development. Epilepsy Res. 60,
161–171. doi: 10.1016/j.eplepsyres.2004.07.001
Timm, F. (1958). Zur Histochemie der Schwermetalle Das Sulfid-Silberverfahren.
Dtsch. Z. Ges. Gerichtl. Med. 46, 706–711.
Uchida, Y., Ohshima, T., Sasaki, Y., Suzuki, H., Yanai, S., Yamashita, N., et al. (2005).
Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phos-
phorylation of CRMP2: implication of common phosphorylating mechanism
underlying axon guidance and Alzheimer’s disease.Genes Cells 10, 165–179. doi:
10.1111/j.1365-2443.2005.00827.x
Uchida, Y., Ohshima, T., Yamashita, N., Ogawara, M., Sasaki, Y., Nakamura, F., et al.
(2009). Semaphorin3A signaling mediated by Fyn-dependent tyrosine phos-
phorylation of collapsin response mediator protein 2 at tyrosine 32. J. Biol.
Chem. 284, 27393–27401. doi: 10.1074/jbc.M109.000240
Wang, Y., Brittain, J. M., Jarecki, B. W., Park, K. D., Wilson, S. M., Wang, B., et al.
(2010). In silico docking and electrophysiological characterization of lacosamide
binding sites on collapsin response mediator protein 2 (CRMP-2) identifies
a pocket important in modulating sodium channel slow inactivation. J. Biol.
Chem. 285, 25296–25307. doi: 10.1074/jbc.M110.128801
Wang, Y., and Khanna, R. (2011). Voltage-gated calcium channels are not affected
by the novel anti-epileptic drug lacosamide. Transl. Neurosci. 2, 13–22. doi:
10.2478/s13380-011-0002-9
Wilson, S. M., Schmutzler, B. S., Brittain, J. M., Dustrude, E. T., Ripsch, M. S.,
Pellman, J. J., et al. (2012a). Inhibition of transmitter release and attenua-
tion of aids therapy-induced and tibial nerve injury-related painful peripheral
neuropathy by novel synthetic Ca2+ channel peptides. J. Biol. Chem. 287,
35065–35077. doi: 10.1074/jbc.M112.378695
Wilson, S. M., Xiong, W., Wang, Y., Ping, X., Head, J. D., Brittain, J. M.,
et al. (2012b). Prevention of posttraumatic axon sprouting by blocking col-
lapsin response mediator protein 2-mediated neurite outgrowth and tubulin
polymerization. Neuroscience 210, 451–466. doi: 10.1016/j.neuroscience.2012.
02.038
Xiong, T., Tang, J., Zhao, J., Chen, H., Zhao, F., Li, J., et al. (2012).
Involvement of the Akt/GSK-3β/CRMP-2 pathway in axonal injury after
hypoxic–ischemic brain damage in neonatal rat.Neuroscience 216, 123–132. doi:
10.1016/j.neuroscience.2012.04.052
Yang, L., Afroz, S., Michelson, H. B., Goodman, J. H., Valsamis, H. A., and
Ling, D. S. (2010b). Spontaneous epileptiform activity in rat neocortex
after controlled cortical impact injury. J. Neurotrauma 27, 1541–1548. doi:
10.1089/neu.2009.1244
Yang, T., Zhou, D., and Stefan, H. (2010a). Why mesial temporal lobe epilepsy with
hippocampal sclerosis is progressive: uncontrolled inflammation drives disease
progression? J. Neurol. Sci. 296, 1–6. doi: 10.1016/j.jns.2010.06.002
Yoshimura, T., Kawano, Y., Arimura, N., Kawabata, S., Kikuchi, A., and Kaibuchi,
K. (2005). GSK-3[beta] Regulates Phosphorylation of CRMP-2 and Neuronal
Polarity. Cell 120, 137–149. doi: 10.1016/j.cell.2004.11.012
Zhang, X., Chen, Y., Ikonomovic, M. D., Nathaniel, P. D., Kochanek, P. M., Marion,
D. W., et al. (2006). Increased phosphorylation of protein kinase B and related
substrates after traumatic brain injury in humans and rats. J. Cereb. Blood Flow
Metab. 26, 915–926. doi: 10.1038/sj.jcbfm.9600238
Zhao, S., Fu, J., Liu, X., Wang, T., Zhang, J., and Zhao, Y. (2012). Activation
of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of
neurons after traumatic brain injury in rats. Neurol. Res. 34, 400–407. doi:
10.1179/1743132812Y.0000000025
Zimmer, J. (1973). Changes in the Timm sulfide silver staining pattern of the
rat hippocampus and fascia dentata following early postnatal deafferentation.
Brain Res. 64, 313–326. doi: 10.1016/0006-8993(73)90186-8
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 05 March 2014; accepted: 29 April 2014; published online: 28 May 2014.
Citation: Wilson SM, Ki Yeon S, Yang X-F, Park KD and Khanna R (2014) Differential
regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by
GSK3ß and CDK5 following traumatic brain injury. Front. Cell. Neurosci. 8:135. doi:
10.3389/fncel.2014.00135
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2014 Wilson, Ki Yeon, Yang, Park and Khanna. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permit-
ted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic prac-
tice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 135 | 14
